New Twice-Yearly shot aims to close cholesterol care gaps in heart disease

NCT ID NCT06249165

Ongoing Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study tests inclisiran, a twice-yearly injection, to help people with heart disease or at high risk for it reach their LDL cholesterol goals. It focuses on groups often understudied, like women, Black, Hispanic, and rural patients. The trial enrolls 130 adults and measures whether they hit target LDL levels after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Inclisiran (a twice-yearly injection to lower LDL cholesterol)
What this could lead to: If successful, inclisiran could offer a convenient, long-acting option to help more people with heart disease reach their cholesterol goals, especially those who are often left out of studies.
What could go wrong: This is a small, early-stage Phase 4 trial with only 130 participants. It may not prove that inclisiran works better than current treatments, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

Contacts and locations

Locations

Baylor Scott & White - Waco

Waco, Texas, 76708, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Emory University

Atlanta, Georgia, 30324, United States
Essentia Health

Duluth, Minnesota, 55805, United States
Heart House of NJ

Haddon Heights, New Jersey, 08035, United States
Houston Methodist

Houston, Texas, 77030, United States
JHU - Suburban Hospital

Bethesda, Maryland, 20814, United States
Johns Hopkins

Columbia, Maryland, 21044, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Medical Univ. of South Carolina

Charleston, South Carolina, 29403, United States
Rush University

Chicago, Illinois, 60612, United States
San Francisco General Hospital

San Francisco, California, 94110, United States
Temple University

Philadelphia, Pennsylvania, 19140, United States
Univ. of Alabama - Birmingham

Birmingham, Alabama, 35205, United States
Univ. of California - Irvine

Orange, California, 92868, United States
University of Iowa

Iowa City, Iowa, 52242, United States
University of Missouri

Columbia, Missouri, 65212, United States
University of Nebraska

Omaha, Nebraska, 68198, United States
University of North Carolina

Chapel Hill, North Carolina, 27514, United States
University of Utah

Salt Lake City, Utah, 84132, United States
Wake Forest University

Winston-Salem, North Carolina, 27157, United States
Washington University

St Louis, Missouri, 63110, United States
Wellstar Paulding

Hiram, Georgia, 30141, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.